Fig. 4: Maternal delivery and Cord-to-maternal antibody transfer ratios timing.

A Maternal delivery anti-SARS-CoV-2 RBD/N IgM antibody level by days since vaccine dose 1 (n = 17, dashed line indicates positive cutoff >50 relative fluorescence units (RFU)). B Maternal delivery anti-SARS-CoV-2 RBD/N IgG antibody level by days since vaccine dose 1 (n = 17, dashed line indicates positive cutoff >50 RFU). C Maternal delivery anti-SARS-CoV-2 RBD/N IgG antibody level by gestational age at vaccine dose 1 (n = 17, dashed line indicates positive cutoff >50 RFU). D Maternal delivery SARS-CoV-2 label-free surrogate neutralization assay (sVNT) antibody titer days since vaccine dose 1 (n = 16, dashed line indicates positive cutoff >25). E Maternal delivery SARS-CoV-2 label-free surrogate neutralization assay (sVNT) antibody titer by gestational age at vaccine dose 1 (n = 16, dashed line indicates positive cutoff >25). A–E Samples with vaccine dose 1 < 30 days prior to delivery (indicated by half circles) excluded from presented analysis. F Cord-to-maternal anti-SARS-CoV-2 RBD/N IgG antibody transfer ratio by cord-to-maternal label-free surrogate neutralization assay (sVNT) antibody transfer ratio (n = 15). G Cord-to-maternal anti-SARS-CoV-2 RBD/N IgG antibody transfer ratio by days since vaccine dose 1 (n = 15). H Cord-to-maternal anti-SARS-CoV-2 RBD/N IgG antibody transfer ratio by gestational age at vaccine dose 1 (n = 15). I Cord-to-maternal SARS-CoV-2 label-free surrogate neutralization assay (sVNT) antibody transfer ratio by days since vaccine dose 1 (n = 15). J Cord-to-maternal SARS-CoV-2 label-free surrogate neutralization assay (sVNT) antibody transfer ratio by gestational age at vaccine dose 1 (n = 15). Spearman’s rank correlation. Two-sided p values were calculated for all test statistics. Source data are provided as a source data file.